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Results: The frequencies of which the small, medium and 
large size plans were used over the (total of 600) fractions 
were similar; plans were used at a median of 9, 9.5 and 10 
fractions respectively. The median volume ratio of PTV-ART 
vs. non-ART across the treatment course was 0.70 (range: 
0.46-0.89). The median rectal volume receiving 50 Gy or 
more was 5% (range: 0-41%), compared to 17% (range: 0-62%) 
if the patients had been treated with standard, non-adaptive 
RT (Fig 1). For the bowel cavity, the median volume receiving 
more than 45 Gy was 392 cm3 (range: 84-625 cm3), compared 
to 487 cm3 (range: 126-710 cm3) if not treated with 
adaptation (Fig 1). 
Conclusions: Daily adaptive plan selection in RT of bladder 
cancer results in a considerable normal tissue sparing, which 
is expected to reduce the risk of gastro-intestinal morbidity. 
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Medical physicists contribute to maintaining and improving 
quality, safety and cost-effectiveness of healthcare services 
through patient-oriented activities requiring expert action, 
involvement or advice regarding the specification, selection, 
acceptance testing, commissioning, quality assurance/control 
and optimised clinical use of medical radiological devices. 
Medical physicists working in a clinical environment are 
healthcare professionals and those at the highest level (level 
8 on the European qualifications framework)are Medical 
Physics Experts(MPEs) competent to practice independently 
in one or more of the subfields (specialties) of medical 
physics; in this way the MPE has the capabilities to tackle 
clinical problems through strategic multidisciplinary 
approaches.  
Today the multidisciplinary approach with medical physicists 
in the clinical environment together with those in the 
commercial industry as well as university research areas is 
mandatory where dosimetry, dosimetric calculation and 
medical imaging for planning and verification needs to be 
approached with a number of different competences. 
Collaboration on clinical research projects between 
commercial partners and medical physicists/MPE should 
therefore be encouraged at all levels. 
Academic partners have the capabilities to develop new 
applications of physics in medicine (linear accelerators, new 
detectors, Monte Carlo simulations, etc.) and have the 
competences required to support such developments. The 
experience derived from protosyncrotony and ion and 
particle accelerator developments in particle research has 
provided fundamental experience to understand what the 
correct approach needs to be to tackle the clinical 
applications.  
Companies have the role to develop hardware and software 
devices for radiotherapy but need medical physics 
competences for testing and optimization "on the field". Many 
advanced medical physics departments are "beta-site" for 
different applications. Pre-release software for treatment 
planning, new treatment modalities, image processing and 
registration technique for Adaptive planning , integrated 
MRI/linear accelerator and high intensity focused ultrasound 
(HIFU) in oncology therapy are typical examples where a 
multidisciplinary approach is essential. A PACS solution for 
radiotherapy is another examples where medical physicists 
are able to define the functional differences between the 
PACS required for radiotherapy compared with the 
requirements for conventional radiology PACS.  
New software for image integration and registration 
techniques must first be validated in clinical practice and the 
multidisciplinary medical physics department is an essential 
partner for companies to create optimized protocols for 
clinical use. 
Finally the medical physicist/MPE is frequently involved in 
training activities  and these experts can also be used to 
inform companies on their development profiles. 
The use of webinar will provide further opportunities for the 
cooperation and training for all the actors involved in 
radiotherapy. 
In conclusion, in order to ensure  that the quality of patient 
treatments is maintained and further improved while  the 
risk of errors is reduced it is necessary that all these 
activities are to be carried out in the clinical working 
environment. In addition many of these activities require 
further development and improvement  within a research 
environment  parallel to the clinical work. 
However, staff often have to carry out research and 
development outside normal working hours due to lack of 
time. This situation is not sustainable and could finally result 
in unsafe patient treatments. It must be realized that 
medical physics departments should have at least an 
additional 0.3 whole time equivalent staffing complement 
(ref. European Guidelines on Medical Physics Expert (Annex 
2)) to carry out these important research and development 
activities. 
References: European Guidelines on Medical Physics Expert, 
Annex 2, Radiation Report No174, European Commission, 
2014  
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In the past decade the introduction of new technologies such 
as IMRT has given a strong boost to medical physics and the 
field of radiation oncology in the US. In the period from 2003 
until 2009 alone, the expenditure for radiation oncology has 
